Patients with metastatic NSCLC stage IV who were treated with anti-PD(L)1 were recruited at Samsung Medical Center (SMC) under the permission of SMC Institutional Review Board (No. 2018-04-048, 2022-01-094). The gene discussed is CD274; the disease is non-small cell lung carcinoma.